
COMPASS Pathways (CMPS) Stock Forecast & Price Target
COMPASS Pathways (CMPS) Analyst Ratings
Bulls say
Compass Pathways PLC is positioned favorably as it advances its proprietary psilocybin therapy, COMP360, especially as it prepares for phase III data release, with a potential increase in stock value contingent on positive results. The company's bolstered probability of success now stands at 75% due to improved regulatory familiarity and robust clinical study outcomes, which indicate significant patient improvements in treatment-resistant depression. Additionally, the development of an expanding global network of treatment centers and further indications under development enhances Compass Pathways's prospect of establishing leadership in the CNS therapeutics sector.
Bears say
Compass Pathways PLC faces significant financial risks, primarily stemming from the potential failure of its lead product, COMP360, to demonstrate clinically meaningful benefits in upcoming Phase III trials, which could severely impact investor sentiment and stock valuation. The company is also burdened by its non-revenue-generating status and substantial ongoing expenses related to research and development and general administrative activities, heightening overall stock price volatility. Additionally, mounting competition in the psychedelic space, coupled with challenges related to regulatory compliance and the commercialization of its products, presents a concerning outlook for the company’s long-term financial stability.
This aggregate rating is based on analysts' research of COMPASS Pathways and is not a guaranteed prediction by Public.com or investment advice.
COMPASS Pathways (CMPS) Analyst Forecast & Price Prediction
Start investing in COMPASS Pathways (CMPS)
Order type
Buy in
Order amount
Est. shares
0 shares